Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $5.00.
Several equities analysts recently issued reports on the company. Oppenheimer decreased their price target on Spruce Biosciences from $4.00 to $3.00 and set an “outperform” rating on the stock in a report on Thursday, June 13th. HC Wainwright reiterated a “neutral” rating on shares of Spruce Biosciences in a research report on Wednesday, June 5th.
Check Out Our Latest Research Report on Spruce Biosciences
Institutional Trading of Spruce Biosciences
Spruce Biosciences Price Performance
Shares of SPRB stock opened at $0.49 on Monday. Spruce Biosciences has a 1 year low of $0.48 and a 1 year high of $5.95. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average is $0.59 and its 200-day moving average is $1.71. The firm has a market capitalization of $19.98 million, a price-to-earnings ratio of -0.43 and a beta of 2.41.
Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.12 million. Spruce Biosciences had a negative return on equity of 57.53% and a negative net margin of 461.67%. Sell-side analysts forecast that Spruce Biosciences will post -1.24 EPS for the current fiscal year.
Spruce Biosciences Company Profile
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
Further Reading
- Five stocks we like better than Spruce Biosciences
- How to invest in marijuana stocks in 7 stepsĀ
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- The Role Economic Reports Play in a Successful Investment Strategy
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What to Know About Investing in Penny Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.